Related Experiment Videos
Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas
N Sadanaga1, H Nagashima, K Mashino
1Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546 Tsurumihara, Beppu 874-0838, Japan.
Abstract:
The MAGE gene is selectively expressed in cancer tissues such as melanoma or gastrointestinal carcinomas, whereas no expression is observed in normal tissues except testis. There are several reports of successful induction of HLA class I-restricted antitumor CTLs using MAGE peptides, and some clinical trials with these immunogenic peptides were reported as effective for some patients with malignant melanoma. However, there are no similar studies in gastrointestinal carcinomas, which are important neoplasms. Autologous dendritic cells (DCs) were generated ex vivo and were pulsed with MAGE-3 peptide, depending on the patient's HLA haplotype (HLA-A2 or A24). Patients were immunized with DC pulsed with MAGE-3 peptide every 3 weeks at four times. Twelve patients with advanced gastrointestinal carcinoma (six stomach, three esophagus, and three colon) were treated, and no toxic side effects were observed. Peptide-specific CTL responses after vaccination were observed in four of eight patients. Improvement in performance status was recognized in four patients. Tumor markers decreased in seven patients. In addition, minor tumor regressions evidenced by imaging studies were seen in three patients. These results suggested that DC vaccination with MAGE-3 peptide is a safe and promising approach in the treatment of gastrointestinal carcinomas.
Insights
Dendritic cell (DC) vaccination using MAGE-3 peptides showed promise for gastrointestinal carcinomas. This approach was safe and induced anti-tumor immune responses in some patients, with positive clinical outcomes observed.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- MAGE genes are expressed in various cancers, including gastrointestinal carcinomas, but not in normal tissues (except testis).
- MAGE peptides have successfully induced anti-tumor cytotoxic T lymphocytes (CTLs) in melanoma patients, but studies in gastrointestinal carcinomas are lacking.
Purpose of the Study:
- To evaluate the safety and efficacy of dendritic cell (DC) vaccination with MAGE-3 peptide in patients with advanced gastrointestinal carcinoma.
Main Methods:
- Autologous DCs were generated ex vivo and pulsed with MAGE-3 peptide, matched to patient HLA haplotype (HLA-A2 or A24).
- Twelve patients with advanced gastrointestinal carcinoma received four immunizations every three weeks.
Main Results:
- The DC vaccination was safe, with no toxic side effects observed.
- Peptide-specific CTL responses were detected in 4 out of 8 evaluable patients.
- Four patients showed improved performance status, seven had decreased tumor markers, and three exhibited minor tumor regressions.
Conclusions:
- DC vaccination with MAGE-3 peptide is a safe and potentially effective therapeutic strategy for gastrointestinal carcinomas.
- This approach warrants further investigation for treating these important neoplasms.